Nothing Special   »   [go: up one dir, main page]

AR122456A2 - TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES - Google Patents

TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES

Info

Publication number
AR122456A2
AR122456A2 ARP210101150A ARP210101150A AR122456A2 AR 122456 A2 AR122456 A2 AR 122456A2 AR P210101150 A ARP210101150 A AR P210101150A AR P210101150 A ARP210101150 A AR P210101150A AR 122456 A2 AR122456 A2 AR 122456A2
Authority
AR
Argentina
Prior art keywords
pyrido
tetrahydro
modulators
indols
estrogen receptors
Prior art date
Application number
ARP210101150A
Other languages
Spanish (es)
Inventor
Simon Charles Goodacre
Sharada Labadie
Jun Liang
Daniel Fred Ortwine
Nicholas Charles Ray
Xiaojing Wang
Jason Zbieg
Birong Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR122456A2 publication Critical patent/AR122456A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen compuestos tetrahidro-pirido[3,4-b]indol1-ilo con actividad o función de modulación de los receptores de estrógenos modulación, que tienen la estructura de la fórmula (1), y los estereoisómeros, tautómeros o sales farmacéuticamente aceptables de los mismos, con los sustituyentes y características estructurales aquí descritos. Se describen también composiciones farmacéuticas y medicamentos que incluyen los compuestos de la fórmula (1), así como métodos de uso de tales moduladores de receptores de estrógenos, solos o en combinación con otros agentes terapéuticos, para tratar enfermedades o estados patológicos que están mediados o dependen de receptores de estrógenos.Tetrahydro-pyrido[3,4-b]indol1-yl compounds with estrogen receptor modulation activity or function, having the structure of formula (1), and the stereoisomers, tautomers or pharmaceutically acceptable salts of the same, with the substituents and structural characteristics described herein. Pharmaceutical compositions and medicaments including the compounds of formula (1) are also described, as well as methods of using such estrogen receptor modulators, alone or in combination with other therapeutic agents, to treat diseases or pathological conditions that are mediated or They depend on estrogen receptors.

ARP210101150A 2014-12-18 2021-04-28 TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES AR122456A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
AR122456A2 true AR122456A2 (en) 2022-09-14

Family

ID=58672209

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150104155A AR103081A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PIRIDO [3,4-B] INDULES MODULATORS OF RECEPTORS OF ESTROGENS AND USES OF THE SAME
ARP210101150A AR122456A2 (en) 2014-12-18 2021-04-28 TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150104155A AR103081A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PIRIDO [3,4-B] INDULES MODULATORS OF RECEPTORS OF ESTROGENS AND USES OF THE SAME

Country Status (2)

Country Link
AR (2) AR103081A1 (en)
MA (1) MA41172B1 (en)

Also Published As

Publication number Publication date
MA41172B1 (en) 2020-09-30
AR103081A1 (en) 2017-04-12

Similar Documents

Publication Publication Date Title
CO2017003070A2 (en) Estrogen receptor modulating tetrahydro-pyrido [3,4-b] indoles and uses thereof
CR20170563A (en) BENZOXACEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE.
PE20151416A1 (en) SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES
NI201900039A (en) DERIVATIVES OF 6, 7, 8, 9-TETRAHIDRO-3H-PIRAZOLO [4, 3-F] ISOQUINOLINE USEFUL IN THE TREATMENT OF CANCER
CL2019000245A1 (en) Moduladores nmda espiro-lactam and methods of use thereof.
CO2018013747A2 (en) Modulators of the spiro-lactam n-methyl-d-aspartate receptor and uses thereof
BR112015020389A2 (en) carbazole compounds useful as bromodomain inhibitors
CL2019000248A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof
EA201591403A1 (en) SPIROLACTAM NMDA RECEPTOR MODULATORS AND THEIR APPLICATION
CO2019010078A2 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods for treating ire1-related diseases and disorders
CL2019000249A1 (en) Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof.
MX2018009257A (en) Benzimidazole derivatives as modulators of ror-gamma.
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
CL2019000246A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof.
PE20151438A1 (en) SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES
CL2019000247A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof.
CO2018005315A2 (en) Modulators of the interaction of sestrina-gator2 and its uses
PE20151427A1 (en) SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES
UY33490A (en) NEW KINOLINE ESTERS USEFUL FOR THE TREATMENT OF SKIN DISORDERS.
CL2017002605A1 (en) Indole derivatives
AR122456A2 (en) TETRAHYDRO-PYRIDO[3,4-B]INDOLS MODULATORS OF ESTROGEN RECEPTORS AND THEIR USES
UY36958A (en) COMPOUNDS FOR INTRACELLULAR ADMINISTRATION
EA202192092A2 (en) TETRAHYDROPIRIDO [3,4-b] INDOLIC ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION
UY35443A (en) OXINDOL DERIVATIVES WITH AN OXETHAN SUBSTITUTE AND USE OF THE SAME TO TREAT VASOPRESINE-RELATED DISEASES